article thumbnail

FDA clears Intellia to start US tests of ‘in vivo’ gene editing drug

Bio Pharma Dive

The announcement, which follows recent regulatory setbacks for some of Intellia’s peers, is a “big win” for the gene editing field, according to one analyst.

article thumbnail

3rd In Vivo Cell Engineering & Gene Editing Summit

pharmaphorum

Achieve Safe & Targeted In Vivo Delivery of Payloads with Clarity in Regulations & Appropriate Models to Advance the Next Frontier of In Vivo Editing from Research to Clinic

In-Vivo 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Sanofi expands research deal with gene editing startup Scribe

Bio Pharma Dive

Scribe will receive $40 million upfront from Sanofi in a collaboration initially focused on developing an in vivo gene editing treatment for sickle cell disease.

article thumbnail

Moderna inks another gene editing deal

Bio Pharma Dive

The messenger RNA specialist said Wednesday it is teaming up with Life Edit Therapeutics to develop therapies that can modify genes “in vivo.”

article thumbnail

€30m raised for first-in-class in vivo cell reprogramming platform

Drug Discovery World

AT-108 is a first-in-class, off-the-shelf gene therapy that directly reprogrammes tumour cells into antigen-presenting dendritic cells, ultimately leading to a personalised anti-tumour immune response. The post €30m raised for first-in-class in vivo cell reprogramming platform appeared first on Drug Discovery World (DDW).

In-Vivo 52
article thumbnail

$175M financing will support development of in vivo CAR-T therapies

Drug Discovery World

The proceeds will be used to advance CPTX2309, Capstan’s lead in vivo chimeric antigen receptor T cell (CAR-T) candidate, to early clinical proof-of-concept in autoimmune disorders, and to further develop Capstan’s tLNP pipeline. Biotechnology company Capstan Therapeutics has raised $175 million in an oversubscribed Series B financing.

In-Vivo 52
article thumbnail

A startup launches with plans to open up a gene and cell therapy bottleneck

Bio Pharma Dive

The pipeline of CAR-T therapies and ex vivo gene therapies has swelled in recent years, but manufacturing hasn’t been able to keep up with demand.

Gene 294